SOPHiA GENETICSTM, a leading cloud-native software firm in the healthcare industry, recently announced that it has partnered with Memorial Sloan Kettering Cancer Center (MSKCC) to provide physicians and researchers with new testing and analytic capabilities.
The collaboration includes the incorporation of proprietary Comprehensive Genomic Panel (CGP) sequencing tests, such as MSK-ACCESS®, which SOPHiA GENETICS will market as the first comprehensive ctDNA liquid biopsy test powered by the SOPHiA DDMTM platform.
By integrating predictive algorithms, the power of the global SOPHiA GENETICS network, and the clinical knowledge of MSK in cancer genomics, specialists hope to broaden their access to capabilities for precision cancer analysis.
SOPHiA GENETICS and MSK will work together to further develop MSK-ACCESS®, ensuring that the solution leverages the advanced analytics of the SOPHiA DDMTM platform. The enhanced assay will be designed to align with the latest guidelines and clinical trial data reflecting major actionable biomarkers.
As part of this agreement, SOPHiA GENETICS plans to develop a new clinical-genomic, cloud-native analytics platform that enhances the impact of MSK��s extensive precision oncology data. This involves the application of sophisticated machine learning algorithms to examine vast amounts of multimodal data points to get new insights. The new SOPHiA CarePathTM module's goal, in conjunction with MSK's CGP sequencing assays, aims to improve cancer care worldwide.
About SOPHiA GENETICS
SOPHiA GENETICS is a cloud-native software company committed to establishing data-driven medicine as the standard of care and for life sciences research. It offers the SOPHiA DDM™ as a cloud-based SaaS platform that enables healthcare organizations to obtain quick and accurate insights from their data. The platform is currently being used by a broad network of hospitals, laboratories, and biopharma institutions globally. By applying its technology to diseases such as cancer and hereditary disorders, it facilitates the integration of genomic and phenotypic data, which is crucial for supporting discoveries, treatment decisions, and drug development activities. In addition, SOPHiA GENETICS supports its mission of bringing data analytics solutions to market through the global adoption of SOPHiA AI, built using techniques such as statistical inference, pattern recognition, and machine learning.